Table of Contents Author Guidelines Submit a Manuscript
BioMed Research International
Volume 2015, Article ID 413076, 21 pages
http://dx.doi.org/10.1155/2015/413076
Review Article

Paclitaxel and Its Evolving Role in the Management of Ovarian Cancer

1Department of Immunology, Monash University, Level 6, The Alfred, Commercial Road, Melbourne, VIC 3181, Australia
2Gynaeoncology Unit, Royal Women’s Hospital, 20 Flemington Road, Parkville, Melbourne, VIC 3052, Australia
3Department of Obstetrics and Gynaecology, University of Melbourne, Melbourne, VIC 3052, Australia

Received 20 February 2015; Accepted 7 April 2015

Academic Editor: Rohit S. Mulik

Copyright © 2015 Nirmala Chandralega Kampan et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Abstract

Paclitaxel, a class of taxane with microtubule stabilising ability, has remained with platinum based therapy, the standard care for primary ovarian cancer management. A deeper understanding of the immunological basis and other potential mechanisms of action together with new dosing schedules and/or routes of administration may potentiate its clinical benefit. Newer forms of taxanes, with better safety profiles and higher intratumoural cytotoxicity, have yet to demonstrate clinical superiority over the parent compound.